166 related articles for article (PubMed ID: 35298286)
1. Amniotic Membrane Grafting for Ocular Surface Inflammation Following Topical Interferon Alpha 2b Therapy.
Shah SG; Mishra DK; Shah GY
J Interferon Cytokine Res; 2022 Mar; 42(3):137-139. PubMed ID: 35298286
[TBL] [Abstract][Full Text] [Related]
2. Role of topical interferon alpha-2b in 'mitomycin-C-resistant' ocular surface squamous neoplasia: our preliminary findings.
Singh M; Gautam N; Kaur M
Int Ophthalmol; 2019 Feb; 39(2):295-301. PubMed ID: 29362973
[TBL] [Abstract][Full Text] [Related]
3. Long term study of topical interferon α-2b eye drops as primary treatment of ocular surface squamous neoplasia.
Sripawadkul W; Reyes-Capo D; Zein M; Wylegala A; Albayyat G; Galor A; Karp CL
Ocul Surf; 2023 Apr; 28():108-114. PubMed ID: 36592780
[TBL] [Abstract][Full Text] [Related]
4. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification.
Shah SU; Kaliki S; Kim HJ; Lally SE; Shields JA; Shields CL
Arch Ophthalmol; 2012 Feb; 130(2):159-64. PubMed ID: 22332208
[TBL] [Abstract][Full Text] [Related]
5. Topical Interferon α-2b as a Single Therapy for Primary Ocular Surface Squamous Neoplasia.
Kusumesh R; Ambastha A; Sinha B; Kumar R
Asia Pac J Ophthalmol (Phila); 2015; 4(5):279-82. PubMed ID: 26176194
[TBL] [Abstract][Full Text] [Related]
6. Mitomycin C or interferon as adjuvant therapy to surgery for ocular surface squamous neoplasia: comparative study.
Blasi MA; Maceroni M; Sammarco MG; Pagliara MM
Eur J Ophthalmol; 2018 Mar; 28(2):204-209. PubMed ID: 28967069
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.
Venkateswaran N; Mercado C; Galor A; Karp CL
Am J Ophthalmol; 2019 Mar; 199():216-222. PubMed ID: 30471241
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of Topical Interferon Alpha-2b Eye Drop as an Adjunctive Therapy Following Surgical Resection in Ocular Surface Squamous Neoplasia.
Kanaya R; Kase S; Ishijima K; Ishida S
In Vivo; 2019; 33(6):2211-2215. PubMed ID: 31662558
[TBL] [Abstract][Full Text] [Related]
9. Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia.
Sturges A; Butt AL; Lai JE; Chodosh J
Ophthalmology; 2008 Aug; 115(8):1297-302, 1302.e1. PubMed ID: 18294690
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of topical 5-fluorouracil in conjunctival intraepithelial neoplasia refractory to interferon alpha-2b.
Pérez-García P; Burgos-Blasco B; Gómez-Calleja V; Vidal-Villegas B; Méndez-Fernández R; Gegúndez-Fernández JA; Díaz-Valle D
J Oncol Pharm Pract; 2023 Jun; 29(4):975-979. PubMed ID: 36131486
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.
Alvarado-Castillo B; Santa Cruz-Pavlovich FJ; Gonzalez-Castillo C; Vidal-Paredes IA; Garcia-Benavides L; Rosales-Gradilla ME; Navarro-Partida J
BMC Ophthalmol; 2023 Jul; 23(1):335. PubMed ID: 37501105
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological characteristics of ocular surface squamous neoplasia in an Asian population.
Kim BH; Kim MK; Wee WR; Oh JY
Graefes Arch Clin Exp Ophthalmol; 2013 Nov; 251(11):2569-73. PubMed ID: 24006080
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of amniotic membrane transplantation combined with mitomycin C for conjunctival reconstruction after ocular surface squamous neoplasia excision.
Hanada K; Nishikawa N; Miyokawa N; Yoshida A
Int Ophthalmol; 2017 Feb; 37(1):71-78. PubMed ID: 27061904
[TBL] [Abstract][Full Text] [Related]
14. Interferon Alfa-2b for Pigmented Ocular Surface Squamous Neoplasia: A Report of 8 Lesions.
Kaliki S; Sharma A; Vempuluru VS
Cornea; 2021 Feb; 40(2):142-146. PubMed ID: 32355112
[TBL] [Abstract][Full Text] [Related]
15. Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia.
Wotman KL; Chow L; Martabano B; Pezzanite LM; Dow S
Cancer Immunol Immunother; 2023 May; 72(5):1185-1198. PubMed ID: 36367558
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
Besley J; Pappalardo J; Lee GA; Hirst LW; Vincent SJ
Am J Ophthalmol; 2014 Feb; 157(2):287-293.e2. PubMed ID: 24184223
[TBL] [Abstract][Full Text] [Related]
17. Successful management of conjunctival intraepithelial neoplasia by interferon alpha-2b.
Kobayashi A; Yoshita T; Uchiyama K; Shirao Y; Kitagawa K; Fujisawa A; Tseng SC
Jpn J Ophthalmol; 2002; 46(2):215-7. PubMed ID: 12062230
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment for ocular surface squamous neoplasia.
Monroy D; Serrano A; Galor A; Karp CL
Eye (Lond); 2023 Apr; 37(5):885-893. PubMed ID: 36754986
[TBL] [Abstract][Full Text] [Related]
19. The regression time of ocular surface squamous neoplasia using topical interferon alfa-2b does not depend on the initial tumor size.
Vilaltella M; Huerva V
Arq Bras Oftalmol; 2021; 85(2):109-114. PubMed ID: 34431893
[TBL] [Abstract][Full Text] [Related]
20. Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications.
Nanji AA; Moon CS; Galor A; Sein J; Oellers P; Karp CL
Ophthalmology; 2014 May; 121(5):994-1000. PubMed ID: 24411578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]